Advertisement

Der Gynäkologe

, Volume 36, Issue 6, pp 507–514 | Cite as

Unkonventionelle Heilmethoden in der Onkologie—Was gibt es Neues?

  • K. Münstedt
  • R. von Georgi
  • M. Zygmunt
Zum Thema
  • 73 Downloads

Zusammenfassung

Unkonventionelle Heilmethoden erfreuen sich besonders in der Onkologie zunehmender Beliebtheit. Trotz zunehmender Bemühungen um eine wissenschaftliche Erforschung einzelner Methoden konnte bisher kein ausreichender Beweis für deren Wirksamkeit und prognostische Bedeutung erbracht werden. In diesem Übersichtsartikel werden die Grundlagen und jüngeren Forschungsergebnisse zur Misteltherapie, Therapie mit Organpräparaten, Enzymtherapie, Hochdosisvitamintherapie, Selensupplementation und zu diätetischen Maßnahmen vorgestellt. Da nach wie vor das Verhältnis von Risiko und möglichen Vorteilen nicht geklärt ist, sollte sich der Einsatz der Methoden auf Studien oder dokumentierten Beobachtungen beschränken, da manche Methoden selbst schädlich sein können oder aber durch Interaktionen, z. B. mit Zytostatika, den Behandlungserfolg orthodoxer Therapien gefährden.

Schlüsselwörter

Alternativmedizin Unkonventionelle Heilmethoden Krebs Misteltherapie 

Abstract

Unconventional cancer therapies are becoming increasingly popular throughout the world. In spite of ongoing efforts for a scientific evaluation of these methods, so far no evidence exists on efficacy or prognostic relevance. This review summarises the basic facts and recent findings on mistletoe treatment, therapy with organ extracts, enzyme therapy, megavitamins, supplementation with selenium, and cancer related diets. Because of the unknown relationship between potential benefits and harm, the use of unconventional methods should be restricted to trials or have the intention of later analysis. These restrictions are due to the fact that harmful effects in some methods as well as pharmacological interactions with cytostatic drugs have been observed.

Keywords

Alternative Unconventional Cancer Mistletoe 

Literatur

  1. 1.
    Abe T, Abe Y, Aida Y, Hara Y, Maeda K (2001) Extracellular matrix regulates induction of alkaline phosphatase expression by ascorbic acid in human fibroblasts. J Cell Physiol 189: 144–151CrossRefPubMedGoogle Scholar
  2. 2.
    Barrett S (2003) MICOM: The dark side of Linus Pauling's legacy. Quackwatch Web site/High dose of vitamin C are not effective as a cancer treatment. http://www.quackwatch.comGoogle Scholar
  3. 3.
    Beuth J, Schierholz JM, Ko HL, Braun JM (2001) Application-dependent immunomodulating and antimetastatic efficacy of thymic peptides in BALB/c-mice. In Vivo 15: 403–406PubMedGoogle Scholar
  4. 4.
    Beuth J, Ost B, Pakdaman A et al. (2001) Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients—results of an epidemiological multicentre retrolective cohort study. Cancer Chemother Pharmacol 47 Suppl: S45–54CrossRefGoogle Scholar
  5. 5.
    Boucher F, Coudray C, Tirard V et al. (1995) Oral selenium supplementation in rats reduces cardiac toxicity of adriamycin during ischemia and reperfusion. Nutrition 11: 708–711PubMedGoogle Scholar
  6. 6.
    Burstein HJ, Gelber S, Guadagnoli E, Weeks JC (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340: 1733–1739CrossRefPubMedGoogle Scholar
  7. 7.
    Clemente C, Belli F, Mascheroni L et al. (1996) Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients. Melanoma Res 6: 63–69CrossRefPubMedGoogle Scholar
  8. 8.
    Creagan ET, Moertel CG, O'Fallon JR et al. (1979) Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301: 687–690CrossRefPubMedGoogle Scholar
  9. 9.
    Dale PS, Tamhankar CP, George D, Daftary GV (2001) Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects. Cancer Chemother Pharmacol 47 Suppl: S29–34CrossRefGoogle Scholar
  10. 10.
    Di Lauro L, Del Medico P, Carpano S et al. (1995) Sequential subcutaneous thymopentin, interferon alpha-2a and interleukin-2 in metastatic renal cell cancer. Tumori 81: 42–44CrossRefGoogle Scholar
  11. 11.
    Duffield-Lillico AJ, Reid ME, Turnbull BW et al. (2002) Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11: 630–639PubMedGoogle Scholar
  12. 12.
    Ernst E (2001) A primer of complementary and alternative medicine commonly used by cancer patients. Med J Aust 175: 88–92Google Scholar
  13. 13.
    Friess H, Berger HG, Kunz J, Funk N, Schilling M, Buchler MW (1996) Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Anticancer Res 16: 915–920PubMedGoogle Scholar
  14. 14.
    Garland M, Morris JS, Stampfer MJ, Colditz GA, Spate VL, Baskett CK, Rosner B, Speizer FE, Willett WC, Hunter DJ (1995) Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst 87: 497–505CrossRefPubMedGoogle Scholar
  15. 15.
    Gebbia V, Valenza R, Testa A, Cannata G, Borsellino N, Gebbia N (1994) A prospective randomized trial of thymopentin vs. granulocyte--colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy. Anticancer Res 14: 731–734PubMedGoogle Scholar
  16. 16.
    Goebell PJ, Otto T, Suhr J, Rubben H (2002) Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol 168: 72–75CrossRefPubMedGoogle Scholar
  17. 17.
    Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R (2001) Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment. Prospective nonrandomized and randomized matched-pair studies nested with a cohort study. Altern Ther Health Med 7: 57–66PubMedGoogle Scholar
  18. 18.
    Gujral MS, Patnaik PM, Paul R, Parikh HK, Conradt C, Tamhankar CP, Daftary GV (2001) Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers. Cancer Chemother Pharmacol 47 Suppl: S23–28CrossRefGoogle Scholar
  19. 19.
    Heiny B-M, Beuth J (1994) Das Lektin der Mistel als Immunmodulator: Effektorwirkung auf β-Endorphin und Zytokinfreisetzung bei Mammakarzinompatientinnen. Dtsch Zschr Onkol 26: 103–107Google Scholar
  20. 20.
    Heiny B-M, Albrecht V, Beuth J (1998) Lebensqualitätsstabilisierung durch Mistellektin-1 normierten Extrakt beim fortgeschrittenen kolorektalen Karzinom. Onkologe 4 (Suppl 1): S 35–39CrossRefGoogle Scholar
  21. 21.
    Henson DE (1999) Cancer and the Internet. Cancer 86: 373–374CrossRefPubMedGoogle Scholar
  22. 22.
    Iaffaioli RV, Frasci G, Tortora G, Ciardiello F, Nuzzo F, Scala S, Pacelli R, Bianco AR (1988–89) Effect of thymic extract 'thymostimulin' on the incidence of infections and myelotoxicity during adjuvant chemotherapy for breast cancer. Thymus 12: 69–75PubMedGoogle Scholar
  23. 23.
    Kiremidjian-Schumacher L, Roy M, Glickman R, Schneider K, Rothstein S, Cooper J, Hochster H, Kim M, Newman R (2000) Selenium and immuncompetence in patients with head and neck cancer. Biol Trace Elem Res 73: 97–111CrossRefPubMedGoogle Scholar
  24. 24.
    Kleijnen J, Knipschild P (1994) Mistletoe treatment for cancer: review of controlled trials in humans. Phytomedicine 1: 255–260CrossRefPubMedGoogle Scholar
  25. 25.
    Krege S, Hinke A, Otto T, Rubben H (2002) Bewertung des Komplementärtherapeutikums Factor AF2 als Supportivum in der Behandlung des fortgeschrittenen Urothelkarzinoms. Urologe A 41: 164–168CrossRefPubMedGoogle Scholar
  26. 26.
    Lamm DL, Riggs DR, Shriver JS, vanGilder PF, Rach JF, DeHaven JL (1994) Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 151: 21–26CrossRefPubMedGoogle Scholar
  27. 27.
    Lenartz D, Stoffel B, Menzel J, Beuth J (1996) Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 16: 3799–3802PubMedGoogle Scholar
  28. 28.
    Loprinzi CL, Thomé SD (2001) Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 19: 972–979CrossRefPubMedGoogle Scholar
  29. 29.
    Münstedt K, Entezami A, Kullmer U (2000) Onkologische Misteltherapie—zur Anwendung und Bewertung der Wirksamkeit durch Ärzte. Dtsch Med Wochenschr 125: 1222–1226CrossRefPubMedGoogle Scholar
  30. 30.
    Münstedt K, Hauenschild A (2001) Ernährung und Ernährungstherapie in der Onkologie. In: Wischnik A (Hrsg) Kompendium Gynäkologie und Geburtshilfe: Weiterbildungsinhalte und Facharztstandards. Landsberg/Lech 1. Erg. Lfg 12/2001, Kap. I-10, pp1–16Google Scholar
  31. 31.
    Münstedt K, Kirsch K, Milch W, Sachsse S, Vahrson H (1996) Unconventional cancer therapy—survey of patients with gynaecological malignancy. Arch Gynecol Obstet 258: 81–88PubMedGoogle Scholar
  32. 32.
    Popiela T, Kulig J, Hanisch J, Bock PR (2001) Influence of a complementary treatment with oral enzymes on patients with colorectal cancers--an epidemiological retrolective cohort study. Cancer Chemother Pharmacol 47 Suppl: S55–63CrossRefGoogle Scholar
  33. 33.
    Risberg T, Lund E, Wist E, Kaasa S, Wilsgaard T (1998) Cancer patient use of nonproven therapy: a 5-year follow-up study. J Clin Oncol 16: 6-12CrossRefPubMedGoogle Scholar
  34. 34.
    Roch CL, Demark-Wahnefried W (2002) Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 20: 3302–3316CrossRefGoogle Scholar
  35. 35.
    Sakalova A, Bock PR, Dedik L et al. (2001) Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma. Cancer Chemother Pharmacol 47 Suppl: S38–44Google Scholar
  36. 36.
    Sammon AM (1992) A case-control study of diet and social factors in cancer of the esophagus in Transkei. Cancer 69: 860–869CrossRefPubMedGoogle Scholar
  37. 37.
    Singh VK, Biswas S, Mathur KB, Haq W, Garg SK, Agarwal SS (1998) Thymopentin and splenopentin as immunomodulators. Current status. Immunol Res 17: 345–368CrossRefPubMedGoogle Scholar
  38. 38.
    Stauder G, Beaufort F, Streichhan P (1991) Strahlentherapeutische Nebenwirkungen bei Abdominalkrebspatienten und deren Reduktion durch hydrolytische Enzympräparate. Dtsch Zschr Onkol 23: 7-16Google Scholar
  39. 39.
    Stettin A, Schultze JL, Stechemesser E, Berg PA (1990) Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro. Klin Wochenschr 68: 896–900CrossRefPubMedGoogle Scholar
  40. 40.
    Steuer-Vogt MK, Bonkowski V, Ambrosch P, Scholz M, Neiss A, Strutz J, Hennig M, Lenarz T, Arnold W (2001) The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomized controlled clinical trial. Eur J Cancer 37: 23–31CrossRefPubMedGoogle Scholar
  41. 41.
    Fujitani et al. (1973)Google Scholar
  42. 42.
    Koyama et al. (1986)Google Scholar
  43. 43.
    Mathijssen et al. (2002)Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Frauenklinik des Universitätsklinikums GießenDeutschland
  2. 2.Medizinische Psychologie und SoziologieJustus-Liebig-Universität GießenDeutschland
  3. 3.Frauenklinik des Universitätsklinikums GießenGießenDeutschland

Personalised recommendations